Actionable news
All posts from Actionable news
Actionable news in CELG: Celgene Corporation,

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene (CELG) took a step forward toward becoming a major player in the multiple sclerosis treatment market with the announcement Friday of positive results from a late-stage clinical trial of ozanimod.

Two doses of ozanimod demonstrated statistically significant superiority over Biogen's (BIIB) Avonex in reducing the annual relapse rate for patients with relapsing multiple sclerosis, achieving the primary endpoint of the phase III study dubbed "Sunbeam."

Celgene is conducting a second phase III study of ozanimid in multiple sclerosis patients, with results expected in the second quarter.

The positive results from the first phase III...